Last updated: August 8, 2025
Overview of PRISMASOL B22GK 2/2.5
PRISMASOL B22GK is a highly regarded parenteral electrolyte solution used in clinical settings. Its formulation, typically comprising sodium chloride, potassium chloride, calcium chloride, and sodium acetate, aims to replete electrolytes rapidly in patients requiring intravenous therapy. The product is commonly supplied in plastic containers with capacities ranging from 2 to 2.5 liters, ensuring sterile preparation for hospital and healthcare use.
Market Landscape of PRISMASOL B22GK Suppliers
The procurement landscape for PRISMASOL B22GK is characterized by a limited yet concentrated network of manufacturers and authorized distributors globally. The supply chain involves pharmaceutical companies that hold manufacturing licenses, quality certifications, and distribution rights. The suppliers often operate under stringent regulatory oversight by agencies such as the European Medicines Agency (EMA) or the U.S. Food and Drug Administration (FDA).
Key domestic and international suppliers include:
- Fresenius Kabi AG
- Baxter International Inc.
- B. Braun Melsungen AG
- Grifols, S.A.
- Hospira (a Pfizer company)
These industry leaders often produce PRISMASOL B22GK under proprietary or licensed formulations, ensuring compliance with international standards.
Fresenius Kabi AG
Overview: A global leader in infusion solutions, Fresenius Kabi manufactures a broad portfolio of intravenous fluids, including electrolyte solutions like PRISMASOL B22GK. Their products are available in multiple regions, with extensive distribution channels.
Supply Status:
Fresenius Kabi holds manufacturing authorization in multiple jurisdictions and distributes PRISMASOL B22GK through direct sales and a vast network of authorized distributors. Their products adhere to rigorous GMP (Good Manufacturing Practices) protocols, ensuring high quality assurance.
Baxter International Inc.
Overview:
Baxter supplies a comprehensive range of sterile intravenous solutions, including electrolyte replenishment fluids. They often produce formulations equivalent or identical to PRISMASOL B22GK under different branding or generically.
Supply Status:
Baxter's global distribution system ensures broad accessibility, especially in North America, Europe, and Asia. Their products meet international quality and safety standards, with extensive supply chain logistics.
B. Braun Melsungen AG
Overview:
B. Braun provides advanced infusion therapy solutions, including electrolyte mixtures suitable for adult and pediatric patients. Their production facilities are certified under GMP, and their portfolio supports numerous markets.
Supply Status:
B. Braun’s products are distributed globally, with regional manufacturing centers ensuring product availability. Their electrolyte solutions are approved under local regulatory systems, securing widespread access.
Grifols, S.A.
Overview:
Primarily known for plasma-derived products, Grifols also offers electrolyte solutions and related infusion therapies. Their focus on quality and innovation supports their role as a supplier.
Supply Status:
Grifols supplies electrolyte solutions to Europe, Latin America, and select regions, with an emphasis on high-quality standards.
Hospira (Pfizer)
Overview:
Now part of Pfizer, Hospira has historically been a significant supplier of injectable drugs and infusion solutions, including electrolyte-based fluids. Their presence ensures supply continuity in various markets.
Supply Status:
While their primary focus has shifted within Pfizer's broader portfolio, their legacy electrolyte products continue to be accessible through authorized distributors.
Regional and Regulatory Considerations
The availability of PRISMASOL B22GK in plastic containers depends heavily on regional regulatory approvals and distribution rights. In Europe, it falls under the scope of the EMA approval, while in the U.S., similar electrolyte solutions are managed by the FDA. Importation, licensing, and distribution are subject to national regulations and quality standards, influencing supplier choices.
Alternative Sources and Generics
In markets with patent expiration or patent challenges, generic manufacturers may produce equivalent electrolyte solutions in plastic containers. These generics often align with the composition of PRISMASOL B22GK and are supplied through authorized pharmaceutical wholesalers or regional distributors.
Note: Procurement decisions should emphasize supplier authenticity, GMP compliance, and adherence to regional regulatory approvals to ensure patient safety and product efficacy.
Key Points for Healthcare Professionals and Procurement Specialists:
- Verify supplier credentials, GMP certification, and regulatory approval status before procurement.
- Consider regional supply chains and import/export regulations that impact product availability.
- Engage with authorized distributors and preferred supplier networks to mitigate counterfeit and substandard product risks.
- Continuously monitor global manufacturing status, especially during geopolitical or supply chain disruptions.
- Stay aware of potential alternative formulations or generic equivalents compliant with local regulations.
Key Takeaways
- The primary global suppliers of PRISMASOL B22GK in plastic containers include Fresenius Kabi, Baxter, B. Braun, and Grifols, each offering high-quality, regulated products.
- Supply chains are region-specific, influenced by local regulatory approvals, manufacturing licenses, and distribution agreements.
- Procurement should prioritize certified suppliers with validated quality standards to ensure safety and therapeutic efficacy.
- The market is dynamic; ongoing regulatory reviews and patent expirations could introduce new vendors or generic options.
- Coordinated engagement with regional distributors and manufacturer representatives minimizes supply risks and enhances access.
FAQs
1. Can I source PRISMASOL B22GK directly from the manufacturer?
Yes, healthcare institutions can establish direct procurement agreements with manufacturers like Fresenius Kabi or Baxter through authorized regional distributors or via official procurement channels, ensuring product authenticity and quality.
2. Are there equivalent generic versions of PRISMASOL B22GK available?
Generic electrolyte solutions with similar composition are available in various markets, typically produced by alternative licensed manufacturers. Verification of regulatory approval and GMP compliance is essential before use.
3. How does regional regulation impact the supply of PRISMASOL B22GK?
Regulatory frameworks govern approval, importation, and distribution. Some countries may require specific certifications, impacting product availability and supplier choices.
4. What should procurement professionals look for in supplier verification?
Verify GMP certification, regional regulatory approvals, certificate of analysis (CoA), traceability, and supplier reputation. Engaging with authorized distributors minimizes counterfeit risks.
5. Are there foreseeable supply constraints for PRISMASOL B22GK?
Global shortages or manufacturing delays can occur due to supply chain disruptions, regulatory changes, or increased demand. Maintaining an updated supplier network and contingency planning are critical.
References
[1] European Medicines Agency. "PRISMASOL B22GK." EMA database, 2022.
[2] Baxter International. "Electrolyte Solutions Portfolio." 2023.
[3] Fresenius Kabi. "Infusion Solutions and Devices." 2023.
[4] B. Braun Melsungen AG. "Infusion Therapy Products." 2023.
[5] Grifols. "Plasma-derived and electrolyte solutions." 2023.
